A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
← catalyst calendarSponsored by Enanta Pharmaceuticals, Inc (industry) · ENTA — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Basic science
Enrollment
24actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-13 | actual | When the study began enrolling |
| Primary completion | 2025-06-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-13 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- RSV Infection
- Drug Drug Interaction
Interventions
- Drug: EDP-323
- Drug: Midazolam
- Drug: Caffeine
- Drug: Rosuvastatin
Primary outcomes
what the primary-completion date above is the date OFCmax of midazolam, caffeine, and rosuvastatin with and without the coadministration of EDP-323
measured Up to 17 Days
AUC of midazolam, caffeine, and rosuvastatin with and without the coadministration of EDP-323
measured Up to 17 Days
Permalink · ENTA's whole pipeline · Catalyst calendar · Every registered study · What changed